[go: up one dir, main page]

KR900017607A - 프로테이나아제 억제제, 이것의 제조방법 및 이들을 함유한 의약품 - Google Patents

프로테이나아제 억제제, 이것의 제조방법 및 이들을 함유한 의약품 Download PDF

Info

Publication number
KR900017607A
KR900017607A KR1019900006865A KR900006865A KR900017607A KR 900017607 A KR900017607 A KR 900017607A KR 1019900006865 A KR1019900006865 A KR 1019900006865A KR 900006865 A KR900006865 A KR 900006865A KR 900017607 A KR900017607 A KR 900017607A
Authority
KR
South Korea
Prior art keywords
replaced
amino acid
lys
ile
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019900006865A
Other languages
English (en)
Other versions
KR0156246B1 (ko
Inventor
프리츠 한스
겝하르트 볼프강
다스 라틴드라
Original Assignee
권터 수마허, 클라우스 데너
바이엘 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 권터 수마허, 클라우스 데너, 바이엘 악티엔게젤샤프트 filed Critical 권터 수마허, 클라우스 데너
Publication of KR900017607A publication Critical patent/KR900017607A/ko
Application granted granted Critical
Publication of KR0156246B1 publication Critical patent/KR0156246B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)

Abstract

내용 없음

Description

프로테이나아제 억제제, 이것의 제조방법 및 이들을 함유한 의약품
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 인체 비쿠닌의 1차 구조를 나타낸다, 제2도는 de[1-17'78-147]-Met18--Xaa36-Xaa38- 비쿠닌 돌연변이체의 제조; 기초 유전자의 올리고뉴클리오티드 서열을 나타낸다, 제3도은 비쿠닌 유전자(pTZKUN1) 및 de[1-17'78-147]-Met18-비쿠닌 유전자(pTZKUN1) 및 de[1-17'78-147]-Met18-Yaa36-Xaa38-비쿠닌 유전자 돌연벤이체
(pTZKU1XX)의 클로닝을 나타낸다.

Claims (11)

1개 이상의 아미노산이 다른 천연 아미노산으로 대체된 인체 비쿠닌의 21-147번 아미노산 서열을 갖는 프로테이나아제 억제제.
제1항에 있어서, 36,38,45,92,116번 위치의 아미노산 중 1개 이상이 다른 천연 아미노산으로 대체된 프로테이나아제 억제제.
제1항 또는 2항에 있어서,Ala, Gly, Ile, Leu, Phe, Val, Arg,Tyr, Trp, Lys로 되는 군에서 선택된 아미노산 잔기에 의해 대체된 것인 프로테이나아제 억제제.
제1항 내지 제3항중 어느 하나의 항에 있어서, 다음과 같은 대체 조합을 갖는 프로테이나제 억제제.
(A) 36번 위치의 Met가 Leu, Ile, Val, Arg, Phe, Tyr, Trp, Lys로 대체됨; (B) 38번 위치의 Met가 Leu, Arg, Ile, Val, Lys로 대체됨; (C) 45번 위치의 Asn이 천연 아미노산으로 대체됨; (D) 92번 위치의 Arg이 Leu, Ile, Val, Phe, Lys로 대체됨; (E) 94번 위치의Phe가 Leu, Arh, Lys, Ile, Val로 대체됨; (F) 98번 위이의 Trp가 Tyr, Lys, Ile,Val, Phe, Leu,Ala,Gly, Ser로 대체됨; (G)116번 위치의Glu가 Arg, Lys로 대체됨.
제1 내지 제4항중 어느 한 항에 있어서, 1개 이상의 Met잔기가 비-산화성 아미노산으로 대체된 프로테이나제 억제제.
제1항 내지 5항중 어느한 항에 있어서, N-말단의 아미노산잔기에 비쿠닌의 천연 서열 중 1내지 21번 서열로부터 유도된 폴리펩티드가 추가된 프로테이나제 억제제.
제1항 내지 제6항에 있어서, 글리코실화 부위를 갖거나 또는 갖지 않는 프로테이나제 억제제.
제1항 내지 7항에 의한 단백질 억제제로부터 얻어진 프로테이나제 억제 작용을 갖는 단편.
제8항에 있어서, 본질적으로 비쿠닌의 22 내지 77번, 1내지 77번 또는 78내지 147번 위치의 아미노산 서열을 갖는 단편.
※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019900006865A 1989-05-13 1990-05-12 프로테이나제 억제제, 그의 제조방법 및 그를 함유한 의약 Expired - Fee Related KR0156246B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DEP3915689.3 1989-05-13
DEP39156893 1989-05-13
DE3915689 1989-05-13
DE4001244 1990-01-18
DEP4001244.1 1990-01-18

Publications (2)

Publication Number Publication Date
KR900017607A true KR900017607A (ko) 1990-12-19
KR0156246B1 KR0156246B1 (ko) 1998-11-16

Family

ID=25880860

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900006865A Expired - Fee Related KR0156246B1 (ko) 1989-05-13 1990-05-12 프로테이나제 억제제, 그의 제조방법 및 그를 함유한 의약

Country Status (17)

Country Link
US (1) US5407915A (ko)
EP (1) EP0401508B1 (ko)
JP (2) JP3126975B2 (ko)
KR (1) KR0156246B1 (ko)
AT (1) ATE114332T1 (ko)
AU (1) AU623769B2 (ko)
CA (1) CA2016627C (ko)
DE (1) DE59007737D1 (ko)
DK (1) DK0401508T3 (ko)
ES (1) ES2066033T3 (ko)
GR (1) GR3015124T3 (ko)
HU (1) HU214985B (ko)
IE (1) IE65710B1 (ko)
IL (1) IL94349A (ko)
NZ (1) NZ233635A (ko)
PH (1) PH27530A (ko)
PT (1) PT94016B (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
US7078383B2 (en) * 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5409895A (en) * 1990-11-13 1995-04-25 Mochida Pharmaceutical Co., Ltd. Protease inhibitory polypeptides derived from urinary trypsin inhibitor and compositions thereof
ES2124203T3 (es) * 1991-03-01 2004-04-16 Dyax Corp. Inhibidores de la elastasa neutrofila humana y la catepsina g humana.
US5451659A (en) * 1991-11-08 1995-09-19 Mochida Pharmaceutical Co., Ltd. Polypeptide, DNA fragment encoding the same, drug composition containing the same and process for producing the same
IL104327A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
JP2769083B2 (ja) * 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
JP3570558B2 (ja) * 1993-05-01 2004-09-29 持田製薬株式会社 Ｄｎａ断片およびそれを含むベクター、該ベクターによって形質転換された形質転換体、該ベクターを用いる蛋白質の産生方法
US5650394A (en) * 1993-11-04 1997-07-22 Adeza Biomedical Use of urinastatin-like compounds to prevent premature delivery
DK1489097T3 (da) * 1994-01-11 2012-01-09 Dyax Corp Hæmmere af humant plasmin, der er afledt af kunitz-domæner, og nukleinsyrer, der koder for samme
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
AU4868096A (en) * 1995-02-23 1996-09-11 Adeza Biomedical Corporation Polypeptides derived from urinastatin having calcium channel blocking activity and their use to delay premature delivery
ES2263174T3 (es) * 1996-03-11 2006-12-01 Bayer Corporation Bikunina humana.
WO2000037099A2 (en) * 1998-12-22 2000-06-29 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance by using a kunitz-type serine protease inhibitor
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
US6660482B1 (en) * 2000-02-28 2003-12-09 Rhode Island Hospital Inter-alpha-trypsin inhibitor as a marker for sepsis
JP2004538676A (ja) * 2001-03-27 2004-12-24 アウェア， インコーポレイテッド 受信機トランスペアレントｑモード
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DE60333758D1 (de) 2002-06-07 2010-09-23 Dyax Corp Prevention und Verringerung von Ischemia
DK2386310T3 (en) 2002-08-28 2019-02-25 Dyax Corp Methods of preserving organs and tissues
ES2362424T3 (es) * 2003-01-07 2011-07-05 Dyax Corporation Biblioteca del dominio kunitz.
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
CN102307594A (zh) * 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
MA39347B2 (fr) * 2014-02-24 2020-05-29 Takeda Pharmaceuticals Co Protéines de fusion d'uti
CA2942713A1 (en) 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
EA201891388A1 (ru) 2015-12-11 2018-11-30 Дайэкс Корп. Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
CA3174478A1 (en) 2020-03-05 2021-09-10 DiaMedica USA Inc. Ulinastatin polypeptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
FR2599752B1 (fr) * 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
FR2601033B1 (fr) * 1986-07-02 1990-01-19 Transgene Sa Variants de l'alpha-antitryspine humaine glycosylee et procede pour la preparation
EP0255011A3 (en) * 1986-07-29 1988-11-23 Miles Inc. Human inter-alpha-trypsin inhibitor gene

Also Published As

Publication number Publication date
IL94349A0 (en) 1991-03-10
IL94349A (en) 1998-01-04
CA2016627A1 (en) 1990-11-13
DE59007737D1 (de) 1995-01-05
NZ233635A (en) 1991-12-23
AU623769B2 (en) 1992-05-21
EP0401508B1 (de) 1994-11-23
JP2001112492A (ja) 2001-04-24
EP0401508A3 (de) 1991-03-27
JPH03255099A (ja) 1991-11-13
PT94016A (pt) 1991-01-08
IE65710B1 (en) 1995-11-15
PT94016B (pt) 1997-05-28
US5407915A (en) 1995-04-18
IE901713L (en) 1990-11-13
HU903010D0 (en) 1990-09-28
GR3015124T3 (en) 1995-05-31
DK0401508T3 (da) 1995-05-15
ES2066033T3 (es) 1995-03-01
HU214985B (hu) 1998-08-28
JP3126975B2 (ja) 2001-01-22
EP0401508A2 (de) 1990-12-12
KR0156246B1 (ko) 1998-11-16
CA2016627C (en) 2000-08-22
ATE114332T1 (de) 1994-12-15
AU5497090A (en) 1990-11-15
PH27530A (en) 1993-08-18

Similar Documents

Publication Publication Date Title
KR900017607A (ko) 프로테이나아제 억제제, 이것의 제조방법 및 이들을 함유한 의약품
DE10075019I2 (de) Neue Proteine mit TNF-Hemmender Wirkung und ihre Herstellung.
Story et al. Amino-terminal sequence of a large form of basic fibroblast growth factor isolated from human benign prostatic hyperplastic tissue
KR940703860A (ko) 신규한 사람 쿠니즈형 프로테아제 저해제 및 그의 변이체(a novel human kunitz-type protease inhibitor and variants thereof)
KR960705850A (ko) 사람 쿠니즈형 프로테아제 저해인자(human kunitz-type protease inhibitors)
EP1197220A3 (en) Therapeutic methods and compositions based on delta proteins and nucleic acids
KR940703854A (ko) 사람 쿠니즈형 프로테아제 저해제 변이체(a human kunitz-type protease inhibitor variant)
AU5963290A (en) Inhibition of the n-end rule pathway in living cells
EP0152333A3 (en) Cardiac atrial peptides
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
AU579142B2 (en) Purification, cloning and characterization of the gene for interleukin 1
HUT69169A (en) T-cell-suppressive peptide fragments of human myelin basic protein (hmbp) and pharmaceutical compositions containing them
KR920016468A (ko) 항-트롬빈 폴리펩타이드
AU669483B2 (en) Nucleotide sequences and resistance proteins cycloheximide
DE3751398D1 (de) Substrat-Peptide.
MARTIN‐PONTHIEU et al. Cuttlefish sperm protamines: 1. Amino acid sequences of two distinct variants
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
ATE103979T1 (de) Menschliches lymphotoxin.
CO5241360A1 (es) Composiciones de flint y usos de estas
Linder et al. Separation of human pancreatic carboxypeptidase A isoenzymes by high performance liquid chromatography
KR920700287A (ko) 신규의 프로테아제 억제물질 및 그것의 제조방법
KR900702046A (ko) 메티오닌- 특이적 아미노펩티다아제인 mas i 및 mas x의 단리, 정제 및 특성확인

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20010623

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20020722

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20020722

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000